肾切除术与活检标本的microRNA分析:透明细胞肾细胞癌进展与生存的预测因子
研究从肾切除术标本(n=156)和肾脏活检标本(n=46)中分离RNA,分为良性、非进展性和进展性透明细胞肾细胞癌(ccRCC)组,用微阵列分析miRNA并以定量逆转录聚合酶链反应验证。发现20个差异表达miRNA区分非进展性与进展性肿瘤,两个生物标志物特征分别以86.7%敏感度/92.9%特异度区分良性与ccRCC、以93.8%敏感度/83.3%特异度区分非进展性与进展性ccRCC,miR-10a-5p、-10b-5p和-223-3p水平与癌症特异性生存(CSS)相关。
要点
- 肾切除术标本中生物标志物特征区分良性与ccRCC的敏感度86.7%、特异度92.9%。
- 另一特征区分非进展性与进展性ccRCC的敏感度93.8%、特异度83.3%。
- miR-10a-5p、-10b-5p和-223-3p水平与癌症特异性生存相关。
核心结论
- 本研究鉴定出在ccRCC样本中差异表达的miRNA以及与癌症特异性生存相关的miRNA,所发现的生物标志物有潜力识别可能发生进展性ccRCC的患者,且尽管为初步结果,可能有助于基于活检标本区分侵袭性与惰性ccRCC。
研究设计与样本
- 从肾切除术标本(n=156)和肾脏活检标本(n=46)中分离RNA,样本分为良性、非进展性和进展性ccRCC组。
- 用微阵列分析miRNA,并以定量逆转录聚合酶链反应验证。
- 建立生物标志物特征以预测肾切除术和活检标本中的癌症状态,并用Kaplan-Meier和Cox比例风险分析检查癌症特异性生存。
主要发现
- 微阵列分析在比较非进展性与进展性肿瘤时发现20个差异表达miRNA。
- 在肾切除术标本中验证的生物标志物特征区分良性与ccRCC标本的敏感度为86.7%、特异度为92.9%。
- 第二个特征区分非进展性与进展性ccRCC的敏感度为93.8%、特异度为83.3%。
- 这些生物标志物在活检标本中也能区分癌症状态。
- miR-10a-5p、-10b-5p和-223-3p水平与癌症特异性生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify microRNA (miRNA) characteristic of metastatic clear cell renal cell carcinoma (ccRCC) and those indicative of cancer-specific survival (CSS) in nephrectomy and biopsy specimens. We also sought to determine if a miRNA panel could differentiate benign from ccRCC tissue. MATERIALS AND METHODS: RNA was isolated from nephrectomy and kidney biopsy specimens (n = 156 and n = 46, respectively). Samples were grouped: benign, non-progressive, and progressive ccRCC. MiRNAs were profiled by microarray and validated by quantitative reverse transcription-polymerase chain reaction. Biomarker signatures were developed to predict cancer status in nephrectomy and biopsy specimens. CSS was examined using Kaplan-Meier and Cox proportional hazards analyses. RESULTS: Microarray analysis revealed 20 differentially expressed miRNAs comparing non-progressive with progressive tumours. A biomarker signature validated in nephrectomy specimens had a sensitivity of 86.7% and a specificity of 92.9% for differentiating benign and ccRCC specimens. A second signature differentiated non-progressive vs progressive ccRCC with a sensitivity of 93.8% and a specificity of 83.3%. These biomarkers also discriminated cancer status in biopsy specimens. Levels of miR-10a-5p, -10b-5p, and -223-3p were associated with CSS. CONCLUSION: This study identified miRNAs differentially expressed in ccRCC samples; as well as those correlating with CSS. Biomarkers identified in this study have the potential to identify patients who are likely to have progressive ccRCC, and although preliminary, these results may aid in differentiating aggressive and indolent ccRCC based on biopsy specimens.
引用
- Kowalik CG, Palmer DA, Sullivan TB, et al. Profiling microRNA from nephrectomy and biopsy specimens: predictors of progression and survival in clear cell renal cell carcinoma. BJU Int. 2017. PMID: 28432832. doi:10.1111/bju.13886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。